Marguerite L. Monogue, David P. Nicolau

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Dalbavancin (Dalvance, Xydalba) is a semisynthetic lipoglycopeptide approved in 2014 by the US Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency for acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Grampositive isolates in adults. Although originally approved for a twodose regimen, the compound has an extended halflife (t1/2) that enables singledose therapy for ABSSSIs (Dunne et al., 2016a; Dunne et al., 2016b). Dalbavancin has potent in vitro activity against most Grampositive organisms with lower minimum inhibitory concentration (MIC) values than vancomycin and other investigational lipoglycopeptides (i.e. oritavancin, telavancin). It is also active against drugresistant pathogens of concern such as methicillinresistant Staphylococcus aureus (MRSA) and vancomycinresistant enterococci (VRE), except for strains exhibiting vanA resistance.

Original languageEnglish (US)
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
PublisherCRC Press
Number of pages13
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
StatePublished - Jan 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • General Medicine


Dive into the research topics of 'Dalbavancin'. Together they form a unique fingerprint.

Cite this